Hormone-Refractory Prostate Cancer Completed Phase 2 Trials for Zoledronic acid (DB00399)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00636740Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer PatientsTreatment
NCT00151073Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateTreatment